FDA Approves First Biologic to Treat Rare Clotting Disorder
The FDA has licensed Baxter Healthcare's (Deerfield, IL, www.baxter.com) Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening clotting disorder.
The FDA has licensed Baxter Healthcare’s (Deerfield, IL, www.baxter.com) Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening clotting disorder. Ceprotin is a concentrated form of Protein C, a substance normally manufactured in the liver that circulates in the plasma in very small amounts.
Severe congenital Protein C deficiency is a rare genetic defect found in one to two newborns for every million births. This protein plays an important role in controlling blood coagulation by preventing the formation and growth of blood clots. Patients with insufficient levels of Protein C experience abnormally high numbers of blood clots. Patients with severe inherited Protein C deficiency must take oral or injected anticoagulant drugs on a regular basis to avoid blood clots.
Complete absence of Protein C can be fatal. Ceprotin is intended to treat high-risk patients when they are faced with a life-threatening situation from blood clots in the veins, or a severe skin and systemic blood clotting disorder known as Purpura fulminans.
FDA has granted Ceprotin orphan drug status. This designation provides a manufacturer with financial incentives to develop a drug or biologic to treat a rare disease (affecting fewer than 200,000 people in the US). Since 1983, more than 200 drugs and biological products have been brought to market in this way.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
